Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Knee Osteoarthritis Therapy: Recent Advances in Intra-Articular Drug Delivery Systems

Ma L., Zheng X., Lin R., Sun AR., Song J., Ye Z.

Narrative Review on Knee Osteoarthritis, Osteoarthritis, published in Drug Des Devel Ther (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Drug Des Devel Ther (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35547865
PMCID
PMC9081192
DOI
10.2147/dddt.s357386
Citations
50

Abstract (original English)

Drug delivery for osteoarthritis (OA) treatment is a continuous challenge because of their poor bioavailability and rapid clearance in joints. Intra-articular (IA) drug delivery is a common strategy and its therapeutic effects depend mainly on the efficacy of the drug-delivery system used for OA therapy. Different types of IA drug-delivery systems, such as microspheres, nanoparticles, and hydrogels, have been rapidly developed over the past decade to improve their therapeutic effects. With the continuous advancement in OA mechanism research, new drugs targeting specific cell/signaling pathways in OA are rapidly evolving and effective drug delivery is critical for treating OA. In this review, recent advances in various IA drug-delivery systems for OA treatment, OA targeted strategies, and related signaling pathways in OA treatment are summarized and analyzed based on current publications.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansOsteoarthritis, KneeHydrogelsDrug Delivery SystemsInjections, Intra-ArticularNanoparticles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research